GPR40 Screening via Secretory Phospholipase A2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening GPR40 agonists or antagonists face challenges due to the solubility issues of fatty acids, which are potential ligands, and the inhibitory effects of bovine serum albumin, requiring complex procedures and difficult cell culture conditions.
Innovation Solution
A screening method using secretory phospholipase A2 (sPLA2), such as honey bee venom or snake venom phospholipase A2, to activate GPR40-mediated cell stimulating activity, allowing for the identification of substances that alter this activity without relying on fatty acids directly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fatty acids are used as ligands for GPR40 screening, then the screening can identify GPR40 agonists and antagonists, but the solubility of fatty acids in aqueous solvents is poor and they are easily adsorbed to plastics or glass
Solution Approach 1:
The patent introduces secretory phospholipase A2 (sPLA2) as an intermediary substance that hydrolyzes phospholipids to generate fatty acids. This allows the screening system to use water-soluble phospholipid substrates instead of directly using insoluble fatty acids, thereby improving solubility and handling while maintaining screening reliability for identifying GPR40 ligands
Solution Approach 2:
The patent changes the physical and chemical parameters of the ligand system by using phospholipid substrates that are hydrolyzed to fatty acids. This parameter change transforms the ligand from an insoluble fatty acid to a water-soluble phospholipid derivative, resolving the solubility issue while preserving the ability to activate GPR40
2Reliability
If bovine serum albumin is present in the screening system, then physiological conditions are maintained, but it has an inhibitory effect on GPR40 activity stimulated by fatty acid
Solution Approach 1:
The patent extracts and removes bovine serum albumin from the screening system, eliminating its inhibitory effect on GPR40 activity. By conducting the screening in albumin-free conditions, the patent maintains physiological relevance through other means while avoiding the harmful inhibitory interaction between albumin and fatty acid-stimulated GPR40
3Reliability
If fatty acids are used directly in screening, then GPR40 activation can be detected, but the process requires complex procedures and difficult cell culture conditions
Solution Approach 1:
The patent performs preliminary action by using sPLA2 to pre-hydrolyze phospholipids into fatty acids before the fatty acids can interact with GPR40. This preliminary hydrolysis step simplifies the overall screening procedure by eliminating the need for complex fatty acid preparation and handling steps, while still enabling reliable detection of GPR40 activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient screening for substances involved in insulin secretion and cancer proliferation, potentially leading to new treatments for diabetes and related diseases by simplifying the screening process and avoiding the complexities associated with fatty acid solubility and albumin inhibition.
Implementation Method 1
secretory phospholipase A2 (sPLA2), such as honey bee venom or snake venom phospholipase A2, to activate GPR40-mediated cell stimulating activity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.